Global Inequities in Diabetes Technology and Insulin Access and Glycemic Outcomes
JAMA Network Open · 27.08.2025 · 8 (8) · e2528933
DOI: 10.1001/jamanetworkopen.2025.28933 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA Network Open, online erschienen am 27.08.2025. Verfasst von Alzbeta Santova und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Motol University Hospital and Second Faculty of Medicine, Prague, Czechia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin, Insulin Infusion Systems, Health Services Accessibility. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Importance Advanced diabetes technologies such as continuous glucose monitoring (CGM), continuous subcutaneous insulin infusion (insulin pumps [CSII]), and glucometers alongside insulin access represent the criterion standard for managing type 1 diabetes (T1D) in children. Global disparities in their access and reimbursement may be associated with glycemic outcomes.
Objective
To describe how accessibility and reimbursement of advanced diabetes technologies and insulin are associated with glycated hemoglobin (HbA 1c ) levels in centers participating in the SWEET initiative, an international pediatric diabetes registry. Design, Setting, and Participants This global multicenter cross-sectional study collected data from 81 centers in 56 countries. Web-based questionnaires were distributed to representatives of all 121 pediatric diabetes centers participating in the SWEET initiative from March 1 to May 31, 2024, and used to map accessibility of and reimbursement for CGM, CSII, glucometers, and insulin. Reimbursement data were compared with HbA 1c levels using the SWEET Study dataset. Participants included 42 349 children with T1D. Exposures Responses were categorized into 4 groups based on the extent of reimbursement for diabetes technologies and insulin. Main Outcomes and Measures Mean HbA 1c levels across centers calculated from measurements current as of December 31, 2023, analyzed by categories of accessibility of and reimbursement for diabetes technologies and insulin.
Results
Data collected from 81 of 121 SWEET centers (67%) across 56 countries included HbA 1c levels from 42 349 children with T1D (22 021 male [52%]; mean [SD] age, 14.3 [4.4] years; mean [SD] diabetes duration, 6.0 [4.2] years). Universal access with complete reimbursement for all technologies and insulin was reported by 32 centers from 19 countries, while 8 countries reported no reimbursement for any technologies or insulin. Centers with full reimbursement for CSII, CGM, glucometers, and insulin showed mean HbA 1c levels of 7.62% (95% CI, 7.59%-7.64%) to 7.75% (95% CI, 7.73%-7.77%) compared with 9.65% (95% CI, 9.55%-9.71%) to 10.49% (95% CI, 10.40%-10.58%) in centers with no reimbursement and/or no availability ( P < .001 for all items). Conclusions and Relevance This cross-sectional study found that HbA 1c levels were associated with the accessibility of modern diabetes technologies and insulin. Efforts to ensure universal accessibility are required to reduce global inequities and glycemic outcomes for children with T1D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Motol University Hospital and Second Faculty of Medicine, Prague, Czechia.
- First Faculty of Medicine, Charles University, Prague, Czechia.
- Department of Pediatrics, University of Otago, Christchurch, New Zealand.
- Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.
- German Center for Diabetes Research, Munich-Neuherberg, Germany.
- Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Zitieren
APA
Santova, A., de Bock, M., Lanzinger, S., Goldbloom, E. B., Bratina, N., Barcala, C., Alhomaidah, D., Pande, A. R., Guness, P. K., Dzivite-Krisane, I., Limbert, C., Sumnik, Z., & SWEET Study Group (2025). Global Inequities in Diabetes Technology and Insulin Access and Glycemic Outcomes. JAMA Network Open, 8(8), e2528933. https://doi.org/10.1001/jamanetworkopen.2025.28933
Vancouver
Santova A, de Bock M, Lanzinger S, Goldbloom EB, Bratina N, Barcala C, et al. Global Inequities in Diabetes Technology and Insulin Access and Glycemic Outcomes. JAMA Network Open. 2025;8(8):e2528933. doi:10.1001/jamanetworkopen.2025.28933
BibTeX
@article{Santova2025,
author = {Santova, Alzbeta and de Bock, Martin and Lanzinger, Stefanie and Goldbloom, Ellen B and Bratina, Natasa and Barcala, Consuelo and Alhomaidah, Doha and Pande, Arunkumar R and Guness, Pravesh Kumar and Dzivite-Krisane, Iveta and Limbert, Catarina and Sumnik, Zdenek and SWEET Study Group, SWEET Study Group},
title = {Global Inequities in Diabetes Technology and Insulin Access and Glycemic Outcomes},
journal = {JAMA Network Open},
year = {2025},
volume = {8},
number = {8},
pages = {e2528933},
doi = {10.1001/jamanetworkopen.2025.28933}
}
EUVIMED